Tango Therapeutics (TNGX) AI Stock Analysis

• Market Cap: $1.10B
• Dividend Yield: N/A
• Average Volume (3M): 3.69M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.49
• Revenue Growth: 53.28%
• EPS Growth: 21.77%
• Country: US
• Employees: 155
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.14
• Shares Outstanding: 134,594,000
• 10 Day Avg. Volume: 2,972,972
• 30 Day Avg. Volume: 3,694,941
• PEG Ratio: -0.25
• Price to Book (P/B): 1.69
• Price to Sales (P/S): 8.02
• P/FCF Ratio: -2.55
• Enterprise Value/Market Cap: 0.74
• Enterprise Value/Revenue: 12.24
• Enterprise Value/Gross Profit: 12.46
• Enterprise Value/Ebitda: -7.83
• 1Y Price Target: $12.80
• Price Target Upside: 56.67% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -0.88
• Revenue Forecast (FY): $59.49M

• Rating: 48 Neutral
• Price Target: $8.00 ▼(-2.08% Downside)

Tango Therapeutics' overall stock score is primarily influenced by its financial performance, which highlights strong revenue growth but significant profitability and cash flow challenges. Technical analysis provides a neutral outlook, with no strong momentum indicators. The valuation score is low due to the negative P/E ratio and lack of dividend yield, reflecting the company's current focus on growth over profitability.

Positive Factors

Revenue Growth

Exceeding revenue expectations indicates strong demand and successful execution of business strategies, supporting long-term growth.

Clinical Development

Advancing clinical trials for new cancer treatments positions the company as a leader in precision oncology, potentially driving future revenue.

Financial Stability

Securing significant financing enhances financial stability, providing resources for R&D and operational needs, supporting long-term strategic goals.

Negative Factors

Profitability Challenges

Ongoing profitability issues may hinder reinvestment in growth and innovation, impacting long-term financial health and shareholder value.

Negative Cash Flow

Negative cash flows can limit operational flexibility and increase reliance on external financing, posing risks to long-term sustainability.

Return on Equity

Negative ROE suggests inefficiency in utilizing equity to generate profits, potentially deterring investors and affecting capital raising.

Tango Therapeutics Business Overview & Revenue Model

Company Description

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

How the Company Makes Money

Tango Therapeutics generates revenue primarily through partnerships and collaborations with pharmaceutical companies, which may involve licensing agreements for its proprietary drug candidates. Additionally, the company may receive milestone payments as its products progress through various stages of development and regulatory approval. Revenue may also come from grants and funding from research institutions or government bodies aimed at supporting its research initiatives. The company’s ability to monetize its intellectual property and the success of its therapeutic candidates in clinical trials are significant factors contributing to its earnings.

Tango Therapeutics Financial Statement Overview

Summary

Tango Therapeutics demonstrates strong revenue growth and efficient cost management, as seen in its high gross profit margin. However, the company faces significant profitability challenges with persistent losses and negative cash flows. While leverage is low, the negative return on equity and cash flow issues suggest financial instability. Continued focus on improving profitability and cash flow is essential for future stability.

Income Statement

Tango Therapeutics shows a strong gross profit margin, indicating efficient cost management. However, the company struggles with negative net profit and EBIT margins, reflecting ongoing losses. Revenue growth is notable, especially in the TTM period, but profitability remains a challenge.

Balance Sheet

The company's debt-to-equity ratio is relatively low, suggesting manageable leverage. However, the negative return on equity indicates that the company is not generating profit from its equity base. The equity ratio is stable, showing a solid equity position relative to total assets.

Cash Flow

Tango Therapeutics faces negative operating and free cash flows, which are concerning for liquidity. The free cash flow to net income ratio is slightly above 1, indicating that cash flow is closely aligned with net income losses. The negative growth in free cash flow highlights cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	66.50M	42.07M	36.53M	24.86M	37.04M	7.66M
Gross Profit	65.32M	42.07M	36.53M	24.86M	37.04M	6.03M
EBITDA	-103.96M	-143.10M	-111.76M	-109.46M	-57.29M	-51.48M
Net Income	-100.52M	-130.30M	-101.74M	-108.18M	-58.23M	-51.86M
Balance Sheet
Total Assets	210.14M	316.49M	402.57M	436.47M	500.15M	207.25M
Cash, Cash Equivalents and Short-Term Investments	152.81M	257.92M	336.88M	366.13M	485.25M	190.32M
Total Debt	34.76M	36.49M	38.92M	41.13M	1.50M	7.88M
Total Liabilities	50.10M	116.97M	149.46M	186.99M	155.41M	168.65M
Stockholders Equity	160.03M	199.52M	253.11M	249.48M	344.75M	38.60M
Cash Flow
Free Cash Flow	-146.76M	-132.25M	-119.51M	-116.77M	-61.36M	68.97M
Operating Cash Flow	-145.81M	-131.50M	-117.98M	-109.08M	-59.53M	70.07M
Investing Cash Flow	146.91M	86.13M	41.43M	26.40M	-183.43M	-145.47M
Financing Cash Flow	4.09M	47.66M	82.41M	1.61M	357.32M	80.88M

Tango Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.17
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNGX, the sentiment is Positive. The current price of 8.17 is above the 20-day moving average (MA) of 8.03, above the 50-day MA of 7.83, and above the 200-day MA of 4.71, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 52.78 is Neutral, neither overbought nor oversold. The STOCH value of 35.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TNGX.

Tango Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMTX	56 Neutral	$1.24B	―	-17.34%	―	83.36%	22.27%
UPB	56 Neutral	$1.35B	-12.21	-40.80%	―	―	―
SPRY	52 Neutral	$884.20M	―	-45.92%	―	5459.66%	-59.70%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TNGX	48 Neutral	$1.10B	―	-51.65%	―	53.28%	21.77%
PRME	43 Neutral	$608.32M	―	-112.34%	―	647.13%	26.79%
ORKA	41 Neutral	$1.33B	-7.54	-23.05%	―	―	63.85%

Tango Therapeutics Corporate Events

Tango Therapeutics Reports Promising Q3 2025 Results

Tango Therapeutics, Inc., a clinical-stage biotechnology company, focuses on discovering and developing precision cancer medicines using the genetic principle of synthetic lethality.

Tango Therapeutics Advances Innovative Cancer Treatment with S095035 Clinical Trial

Study Overview: Tango Therapeutics, Inc. is collaborating on a Phase 1/2 clinical trial titled A Phase 1/2, Open-label, Multicenter Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of S095035 (MAT2A Inhibitor) as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP. The study aims to assess the safety and effectiveness of the MAT2A inhibitor, S095035, alone and in combination with TNG462, in treating advanced or metastatic solid tumors that have a specific genetic deletion, MTAP. This trial is significant as it targets patients who have limited treatment options.

Revolution Medicines and Tango Therapeutics Advance in Targeted Cancer Therapy Study

Revolution Medicines, Inc. and Tango Therapeutics, Inc. are conducting a clinical study titled ‘A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation.’ The study aims to assess the safety, tolerability, and preliminary antitumor activity of TNG462 combined with RMC-6236 or RMC-9805 in patients with specific genetic mutations. This research is significant as it targets challenging cancer types with limited treatment options.

Tango Therapeutics’ Promising Update on TNG260 Clinical Study

Tango Therapeutics, Inc. is conducting a clinical study titled A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mutated Advanced Solid Tumors. The study aims to determine the recommended dose for Phase 2, assess the safety and tolerability of the combination therapy, and evaluate the pharmacokinetics and initial antineoplastic activity of TNG260 in patients with STK11-mutated solid tumors.

Tango Therapeutics Advances TNG462 Study for MTAP-deleted Tumors

Study Overview: Tango Therapeutics, Inc. is conducting a Phase 1/2 study titled ‘A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors.’ The study aims to assess the safety and effectiveness of TNG462 in treating MTAP-deleted solid tumors, a significant area of unmet medical need.

Tango Therapeutics Announces Major Stock Offering

On October 23, 2025, Tango Therapeutics announced a registered direct offering of 21,023,337 shares of common stock and pre-funded warrants to purchase an additional 3,226,458 shares, expected to raise approximately $197 million. The proceeds will be used to advance the company’s pipeline and support general corporate purposes, with the offering anticipated to close on October 24, 2025. Additionally, Tango entered into a private placement agreement with an accredited investor for 1,732,101 shares, expected to generate $15 million. These financial moves are intended to fund operations and capital expenditures into 2028, strengthening Tango’s position in the biotechnology industry.

The most recent analyst rating on (TNGX) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Tango Therapeutics stock, see the TNGX Stock Forecast page.

Tango Therapeutics Announces Preliminary Financial Results

On October 23, 2025, Tango Therapeutics announced preliminary unaudited financial results, estimating $152.8 million in cash and marketable securities as of September 30, 2025. The company also provided a clinical update on its ongoing Phase 1/2 trial of vopimetostat, highlighting its potential as a best-in-class treatment for MTAP-deleted solid tumors, with plans for a pivotal study in second-line pancreatic cancer to begin in 2026.

The most recent analyst rating on (TNGX) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Tango Therapeutics stock, see the TNGX Stock Forecast page.

Tango Therapeutics’ Chief Legal Officer Resigns

On August 21, 2025, Douglas Barry announced his resignation as Chief Legal and Compliance Officer and Corporate Secretary of Tango Therapeutics, effective September 12, 2025, to pursue another opportunity. This change in leadership may impact Tango Therapeutics’ operations and strategic direction as they adjust to the departure of a key executive.

The most recent analyst rating on (TNGX) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Tango Therapeutics stock, see the TNGX Stock Forecast page.